Moleculin Biotech reports positive preliminary unblinded efficacy results in MIRACLE trial for relapsed, refractory AML

Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

MBRX

0.00
  • Unblinded preliminary results from the first 45 patients in the pivotal Phase 2/3 MIRACLE trial showed positive early efficacy trends for Annamycin in R/R AML.
  • Signals were observed across both Annamycin treatment arms in the randomized, double-blind, placebo-controlled study testing Annamycin plus cytarabine.
  • Management framed the data as supportive of the commercial opportunity for Annamycin if approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607060833PRIMZONEFULLFEED9757078) on July 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.